Therapies for Advanced Colorectal Cancer: The Role of Interferon and Leucovorin

Advanced colorectal cancer meta-analysis project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence of terms of response rate. J. Clin. Oncol., 10: 896–903, 1992.

Doroshow J.H. , Multhauf P. , Leong L. , Margolin K. , Litchfield T. , Akman S. , Carr B. , Bertrand M. , Golberg D. , Blaynay D. , Odujinrin O. , Delap R. , Shuster J. , Newman E. : Prospective randomized comparison of fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously exposed to chemotherapy. J. Clin. Oncol., 7: 491–501, 1990.

Einhorn L.H. : Improvements in fluorouracil chemotherapy? J. Clin. Oncol., 7: 1377–1379, 1989.

Erlichman C. : Development of new thymidylate synthase inhibitors. ASCO Educational Book, pp. 98–101, 1995.

Ernstoff M.S. , Lembersky B.C. , Kirkwood J.M. : Fluorouracil, interferon-alpha, and colon cancer: rational pursuit of synergism between antimetabolites and biologicals. J. Clin. Oncol., 7: 1764–1765, 1989.

Gerstner J. , O'Connell M.J. , Wieand H.S. , Buroker T.R. , Krook J. : A prospectively randomized clinical trial compared 5-FU combined with either high or low dose leucovorin for the treatment of advanced colorectal cancer. Proc. ASCO, 10: 134, 1991.

Greco F.A. , Figlin R. , York M. , Einhorn L. , Schilsky R. , Marshall E.M. , Buys S.S. , Froimtchuk M.J. , Schuller J. , Schuchter L. , Buyse M. , Ritter L. , Man A. , Yap A.K.L. : Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J. Clin. Oncol., 14: 2674–2681, 1996.

Kemeny N. , Kelsen D. , Derby S. : Combination 5-fluorouracil and recombinant alpha-interferon in advanced colorectal carcinoma: activity but significant toxicity. Proc. Am. Soc. Clin. Oncol., 9: 109, 1990.

Kennedy P. , Presant C.A. , Blayney D. : Sandostatin therapy for chemoterapy and radiotherapy related diarrhea. Proc. Am. Soc. Clin. Oncol., 9: 324, 1990.

Leichman C.G. , Fleming T.R. , Muggia F.M. , Tangen C.M. , Ardalan B. , Doroshow J.H. , Meyers F.J. , Holcombe R.F. , Weiss G.R. , Mangalik A. , Macdonald J.S. : Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group Study. J. Clin. Oncol., 13: 1303–1311, 1995.

Lokich J.J. , Ahlgren J.D. , Gullo J.J. , Philips J.A. , Fryer J.G. : A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J. Clin. Oncol., 7: 425–432, 1989.

Mahood D.J. , Dose A.M. , Loprinzi C.L. , Veeder M.H. , Athmann L.M. , Therneau T.M. , Sorensen J.M. , Gainey D.K. , Mailliard J.A. , Gusa N.L. , Finck G.K. , Johnson C. , Goldberg R.M. : Inhibition of fluorouracil induced stomatitis by oral cryotherapy. J. Clin. Oncol., 9: 449–452, 1991.

Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer. J. Clin. Oncol., 6: 904–911, 1992.

O'Dwyer P.J. , Paul A. , Walczak J. , Weiner L.M. , Litwin S. , Comis R.L. : Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J. Clin. Oncol., 8: 1497–1503, 1990.

O'Dwyer P.J. , Ryan L.M. , Valone F.H. , Hines J.D. , Arbuck S.G. , Wadler S. , Haller D.G. , Mayer R.J. , Benson A.B. : Phase III trial of biochemical modulation of 5-fluorouracil by iv or oral leucovorin or by interferon in advanced colorectal cancer. An ECOG/CALGB phase III Trial. Proc. Am. Soc. Clin. Oncol., 15: 207, 1996.

Ogawa M. : New systemic drugs in the treatment of gastrointestinal cancer. Curr. Opin. Oncol., 8: 317–320, 1996.

Pazdur R. , Abbruzzese J. , Faintuch J. , Ajani J. , Patt Y. , Jackson D. , Markowitz A. , Winn R. , Gutterman J. , Levin B. : Phase II study of recombinant interferon alpha and 5-fluorouracil in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol., 9: 117, 1990.

Petrelli N. , Douglass H.Q. Jr. , Herrera L. , Russel D. , Stablein D.M. , Bruckner H.W. , Mayer R.J. , Schinella R. , Green M.D. , Muggia F.M. , Megibow A. , Greenwald E.S. , Bukowski R.M. , Harris J. , Levin B. , Gaynor E. , Loutfi A. , Kelsen M. , Barkin J.S. , Benedetto P. , Woolley P.V. , Nauta R. , Weaver D.W. , Leichman L. : The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J. Clin. Oncol., 7: 1419–1426, 1989.

Poon M.A. , O'Connell M.J. , Moertel C.G. , Wieand H.S. , Culliman S.A. , Everson L.K. , Krook J.E. , Mailliard J.A. , Laurie J.A. , Tschetter L.K. , Wiesenfeld M. : Biochemical modulation of fluorouracil: evidence of significant improvement in survival and quality of life in patients with advanced colorectal cancer. J. Clin. Oncol., 7: 1407–1418, 1989.

Seymour M.T. , Slevin M.L. , Kerr D. , James R.D. , Ledermann J.A. , Perren T.J. , McAdam W.A.F. , Harper P.G. , Neoptolemos J.P. , Nicholson M. , Duffy A.M. , Stephens R.J. , Stenning S.P. , Taylor I. : Randomized trial assessing the addition of interferon α-2a to fluorouracil and leucovorin in advanced colorectal cancer. J. Clin. Oncol., 14: 2280–2288, 1996.

Wadler S. , Schwartz E.L. , Goldman M. , Lyver A. , Rader M. , Zimmerman M. , Itra L. , Weinberg V. , Wiernik P.H. : Fluorouracil and recombinant alpha-2a-interferon: an active regimen against advanced colorectal carcinoma. J. Clin. Oncol., 7: 1769–1775, 1989.